DE60032749D1 - Stabilisierte pharmazeutische zusammensetzung enthaltend einen nichtsteroiden entzündungshemmenden wirkstoff und prostaglandin - Google Patents

Stabilisierte pharmazeutische zusammensetzung enthaltend einen nichtsteroiden entzündungshemmenden wirkstoff und prostaglandin

Info

Publication number
DE60032749D1
DE60032749D1 DE60032749T DE60032749T DE60032749D1 DE 60032749 D1 DE60032749 D1 DE 60032749D1 DE 60032749 T DE60032749 T DE 60032749T DE 60032749 T DE60032749 T DE 60032749T DE 60032749 D1 DE60032749 D1 DE 60032749D1
Authority
DE
Germany
Prior art keywords
prostaglandin
pharmaceutical composition
nsaid
inflammative
teroid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60032749T
Other languages
English (en)
Other versions
DE60032749T2 (de
Inventor
Aomar Ouali
Abul Kalam Azad
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmascience Inc
Original Assignee
Pharmascience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmascience Inc filed Critical Pharmascience Inc
Publication of DE60032749D1 publication Critical patent/DE60032749D1/de
Application granted granted Critical
Publication of DE60032749T2 publication Critical patent/DE60032749T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
DE60032749T 1999-03-22 2000-03-20 Stabilisierte pharmazeutische zusammensetzung enthaltend einen nichtsteroiden entzündungshemmenden wirkstoff und prostaglandin Expired - Lifetime DE60032749T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/273,692 US6183779B1 (en) 1999-03-22 1999-03-22 Stabilized pharmaceutical composition of a nonsteroidal anti-inflammatory agent and a prostaglandin
US273692 1999-03-22
PCT/CA2000/000301 WO2000056339A1 (en) 1999-03-22 2000-03-20 Stabilized pharmaceutical composition of a nonsteroidal anti-inflammatory agent and a prostaglandin

Publications (2)

Publication Number Publication Date
DE60032749D1 true DE60032749D1 (de) 2007-02-15
DE60032749T2 DE60032749T2 (de) 2007-10-18

Family

ID=23045012

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60032749T Expired - Lifetime DE60032749T2 (de) 1999-03-22 2000-03-20 Stabilisierte pharmazeutische zusammensetzung enthaltend einen nichtsteroiden entzündungshemmenden wirkstoff und prostaglandin

Country Status (7)

Country Link
US (2) US6183779B1 (de)
EP (1) EP1162975B1 (de)
AT (1) ATE350040T1 (de)
AU (1) AU3269200A (de)
CA (1) CA2301378C (de)
DE (1) DE60032749T2 (de)
WO (1) WO2000056339A1 (de)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8022095B2 (en) 1996-08-16 2011-09-20 Pozen, Inc. Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
US6319519B2 (en) 1998-07-07 2001-11-20 Norton Healthcare Ltd. Anti-inflammatory pharmaceutical formulations
US6514525B2 (en) 1998-09-10 2003-02-04 Norton Healthcare Ltd Anti-inflammatory pharmaceutical formulations
US6387410B1 (en) * 1998-09-10 2002-05-14 Norton Healthcare Ltd Anti-inflammatory pharmaceutical formulations
JP2003510347A (ja) * 1999-10-01 2003-03-18 ノートン ヘルスケアー リミテッド 抗炎症医薬品製剤
KR20030019326A (ko) * 2000-03-21 2003-03-06 니뽄 신야쿠 가부시키가이샤 방출 제어형 경구 투여 제제
AR030557A1 (es) * 2000-04-14 2003-08-27 Jagotec Ag Una tableta en multicapa de liberacion controlada y metodo de tratamiento
US20020035107A1 (en) 2000-06-20 2002-03-21 Stefan Henke Highly concentrated stable meloxicam solutions
US20020192299A1 (en) * 2000-12-28 2002-12-19 Rajneesh Taneja Pharmaceutical compositions of a non-enteric coated proton pump inhibitor with a carbonate salt and bicarbonate salt combination
US20020177626A1 (en) * 2001-01-19 2002-11-28 Cook Graham D. Treatment of sleep disturbances
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
GB2380937A (en) * 2001-10-18 2003-04-23 David Ian Slovick Method of dispensing a plurality of medical substances into capsules
DE10161077A1 (de) 2001-12-12 2003-06-18 Boehringer Ingelheim Vetmed Hochkonzentrierte stabile Meloxicamlösungen zur nadellosen Injektion
GB2386817B (en) * 2002-02-20 2006-08-23 Walcom Animal Science Feed for fish and use therof
US8323692B2 (en) 2002-02-21 2012-12-04 Valeant International Bermuda Controlled release dosage forms
NZ535456A (en) * 2002-02-21 2006-08-31 Biovail Lab Int Srl Modified release formulations of at least one form of tramadol for oral administration
US20050124699A1 (en) * 2002-07-02 2005-06-09 Wakamoto Pharmaceutical Co., Ltd. Drugs for treating or preventing disorders of corneal and/or conjunctival epithelial cells
US20040082618A1 (en) * 2002-07-03 2004-04-29 Rajneesh Taneja Liquid dosage forms of acid labile drugs
US8992980B2 (en) * 2002-10-25 2015-03-31 Boehringer Ingelheim Vetmedica Gmbh Water-soluble meloxicam granules
US20040121004A1 (en) * 2002-12-20 2004-06-24 Rajneesh Taneja Dosage forms containing a PPI, NSAID, and buffer
US20070243251A1 (en) * 2002-12-20 2007-10-18 Rajneesh Taneja Dosage Forms Containing A PPI, NSAID, and Buffer
WO2004064815A1 (en) * 2003-01-21 2004-08-05 Smartrix Technologies Inc. Oral dosage formulation
DE602004007315D1 (de) * 2003-03-03 2007-08-16 Personnes A Responsibilite Lim Stabilisierte pharmazeutische Zusammensetzung enthaltend einen NSAID und einen Prostaglandin
WO2004091579A1 (en) * 2003-04-16 2004-10-28 Pharmacia Corporation Stabilized prostaglandin formulation
US20050096311A1 (en) * 2003-10-30 2005-05-05 Cns Response Compositions and methods for treatment of nervous system disorders
EP1568369A1 (de) 2004-02-23 2005-08-31 Boehringer Ingelheim Vetmedica Gmbh Verwendung von Meloxicam zur Behandlung von Atemwegserkrankungen bei Schweinen
DE102004021281A1 (de) * 2004-04-29 2005-11-24 Boehringer Ingelheim Vetmedica Gmbh Verwendung von Meloxicam-Formulierungen in der Veterinärmedizin
DE102004030409A1 (de) * 2004-06-23 2006-01-26 Boehringer Ingelheim Vetmedica Gmbh Neue Verwendung von Meloxicam in der Veterinärmedizin
WO2006070406A1 (en) * 2004-12-29 2006-07-06 J.B. Chemicals & Pharmaceuticals Ltd Bilayer tablets of oxcarbazepine for controlled delivery and a process of preparation thereof
US20060177504A1 (en) * 2005-02-08 2006-08-10 Renjit Sundharadas Combination pain medication
US20070053868A1 (en) * 2005-03-08 2007-03-08 Banner Pharmacaps, Inc. Solvent system for enhancing the solubility of pharmaceutical agents
EP1858483A4 (de) * 2005-03-16 2009-07-15 Reddys Lab Ltd Dr System zur abgabe mehrerer arzneimittel
US20070224259A1 (en) * 2005-09-21 2007-09-27 Gupta Anil K Anti-inflammatory pharmaceutical composition
KR20080059269A (ko) * 2005-09-30 2008-06-26 베링거잉겔하임베트메디카게엠베하 멜록시캄을 함유하는 약제학적 제제
US20090304786A1 (en) * 2005-11-25 2009-12-10 Viswaprasad Varanasi Stable Dosage Forms of an Antidepressant
AU2006325658B2 (en) * 2005-12-16 2010-04-08 Hanmi Science Co., Ltd. Solid dispersion comprising an active ingredient having a low melting point and tablet for oral administration comprising same
US20070190139A1 (en) * 2006-02-13 2007-08-16 Intelgenx Corp. Delayed release pharmaceutical oral dosage form and method of making same
EP2124556B1 (de) 2006-10-09 2014-09-03 Charleston Laboratories, Inc. Pharmazeutische zusammensetzungen
EP2167048B1 (de) 2007-05-30 2016-10-26 Wockhardt Limited Neue tabletten-dosierform
US20090012165A1 (en) * 2007-07-03 2009-01-08 Sucampo Ag Pharmaceutical combination of nsaid and prostaglandin compound
EP3090743A1 (de) 2008-01-09 2016-11-09 Charleston Laboratories, Inc. Pharmazeutische zusammensetzungen
US20090214648A1 (en) * 2008-02-15 2009-08-27 Malathi Kandakatla Pharmaceutical formulations comprising ibuprofen and diphenhydramine
MY155652A (en) * 2008-08-22 2015-11-13 Reckitt Benckiser Healthcare Improvements in or relating to compositions
AU2009290712A1 (en) 2008-09-09 2010-03-18 Astrazeneca Ab Method for delivering a pharmaceutical composition to patient in need thereof
US20100233259A1 (en) * 2008-12-12 2010-09-16 Pascal Grenier Dosage form of ropinirole
EP2445499A4 (de) 2009-06-25 2013-02-27 Astrazeneca Ab Verfahren zur behandlung eines patienten mit risiko der entwicklung eines nsaid-assoziierten geschwürs
JP2012531430A (ja) * 2009-06-25 2012-12-10 ポーゼン インコーポレイテッド アスピリン療法を必要とする患者を治療するための方法
EP3311667A1 (de) 2009-07-08 2018-04-25 Charleston Laboratories, Inc. Pharmazeutische zusammensetzungen
JP5559339B2 (ja) * 2009-10-12 2014-07-23 ベーリンガー インゲルハイム フェトメディカ ゲゼルシャフト ミット ベシュレンクテル ハフツング メロキシカムを含む組成物のための容器
KR20130037237A (ko) 2010-03-03 2013-04-15 베링거잉겔하임베트메디카게엠베하 고양이에서 근골격계 장애를 장기간 치료하기 위한 멜록시캄의 용도
US9795568B2 (en) 2010-05-05 2017-10-24 Boehringer Ingelheim Vetmedica Gmbh Low concentration meloxicam tablets
CN102336693B (zh) * 2010-07-21 2014-01-22 上海天伟生物制药有限公司 卡前列素氨丁三醇的晶体及其制备方法和用途
US20140271783A1 (en) * 2011-10-14 2014-09-18 Purdue Research Foundation Prefabricated pharmaceutical dosage forms from functional polymer films
CN104519888A (zh) 2011-12-28 2015-04-15 波曾公司 用于递送奥美拉唑和乙酰水杨酸的改良组合物和方法
CN105435239B (zh) * 2014-08-29 2019-04-26 武汉光谷人福生物医药有限公司 美索舒利薄膜衣片及其制备方法
US9839212B2 (en) 2015-04-16 2017-12-12 Bio-Lab, Inc. Multicomponent and multilayer compacted tablets
US10179109B2 (en) 2016-03-04 2019-01-15 Charleston Laboratories, Inc. Pharmaceutical compositions comprising 5HT receptor agonist and antiemetic particulates

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3781429A (en) 1972-09-29 1973-12-25 American Cyanamid Co Method of inhibiting ulcerogenesis induced by non-steroidal anti-inflammatory agents
US3927213A (en) 1973-07-10 1975-12-16 American Home Prod Prostaglandin E{HD 2 {B and derivatives for reducing the side effects of anti-inflammatory agents
US3928588A (en) 1974-02-22 1975-12-23 Upjohn Co Method of reducing the undesirable gastrointestinal effects of prostaglandin synthetase inhibitors
US3954787A (en) 1974-06-18 1976-05-04 Pfizer Inc. Stabilized E-series prostaglandins
US4301146A (en) 1980-07-29 1981-11-17 G. D. Searle & Co. Stabilization of 16-oxygenated prostanoic acid derivatives
US5015481A (en) 1990-05-03 1991-05-14 G. D. Searle & Co. Stabilized pharmaceutical admixture composition
CA2082944C (en) 1990-05-03 1998-11-24 Rene Antoine Gimet Pharmaceutical compositions
WO1999012524A1 (en) 1997-09-11 1999-03-18 Nycomed Danmark A/S MODIFIED RELEASE MULTIPLE-UNITS COMPOSITIONS OF NON-STEROID ANTI-INFLAMMATORY DRUG SUBSTANCES (NSAIDs)
CA2241342C (en) 1998-06-15 2000-02-08 Bernard Charles Sherman Pharmaceutical tablets comprising an nsaid and a prostaglandin
GB9814215D0 (en) 1998-07-01 1998-09-02 Norton Healthcare Ltd Anti-inflammatory pharmaceutical formulations
GB9819685D0 (en) 1998-09-10 1998-11-04 Norton Healthcare Ltd Anti-inflammatory pharmaceutical formulations

Also Published As

Publication number Publication date
US6183779B1 (en) 2001-02-06
AU3269200A (en) 2000-10-09
CA2301378C (en) 2005-07-26
US6287600B1 (en) 2001-09-11
EP1162975A1 (de) 2001-12-19
CA2301378A1 (en) 2000-09-22
ATE350040T1 (de) 2007-01-15
WO2000056339A1 (en) 2000-09-28
EP1162975B1 (de) 2007-01-03
DE60032749T2 (de) 2007-10-18

Similar Documents

Publication Publication Date Title
DE60032749D1 (de) Stabilisierte pharmazeutische zusammensetzung enthaltend einen nichtsteroiden entzündungshemmenden wirkstoff und prostaglandin
NO20061859L (no) OROS Push Stick for kontrollert tilforsel av aktive midler
ATE215816T1 (de) Feste oral anzuwendende arzeneiform
JP2005515966A5 (de)
PE20040134A1 (es) Forma de dosificacion de una vez al dia de pramipexol
US20070184109A1 (en) Compositions comprising triptans and nsaids
RS52577B (en) ONE-DAY OXYCODON FORMULATIONS
ATE424810T1 (de) Ein hydrokolloid und einen celluloseether enthaltende tablette mit verzögerter freisetzung
SG157406A1 (en) Oral medicament for the modified release of at least one active principle, in multi-microcapsule form
BR9814378A (pt) Forma de dosagem de liberação prolongada farmacêutica revestida entérica de um inibidor de h+, k+-atpase, processos para a manufatura da mesma, para melhorar a inibição de secreção de ácido gástrico, para melhorar o efeito terapêutico no tratamento de distúrbios gastrointentinais, para receber um perfil de plasma prolongado de um inibidor da h+, k+-atpase, e, usos de uma composição farmacêutica e de inibidor da h+, k+-atpase
JP2008543936A5 (de)
AR045289A1 (es) Forma de dosificacion oral de liberacion controlada que comprende 4-(2-di-n-propilaminoetil) - 2(3h)-indolona (ropi-nirol) y uso de dicha forma de dosificacion para la elaboracion de un medicamento
HRP20110497T4 (hr) Postupci za primjenu kompozicija aminopiridina sa produženim oslobađanjem
WO2006072940A3 (en) Controlled long acting release pharmaceutical preparation for use in the oral cavity
RS54050B1 (en) FORMULATIONS AND METHODS FOR THE TREATMENT OF AMYLOIDOSIS
AP2003002763A0 (en) Controlled release formulations for oral administration
AR046036A1 (es) Composiciones de risedronato y metodos para su uso
BR0013719A (pt) Dosagem oral de liberaçâo controlada, apropriada para administração oral
US7303761B2 (en) Stabilised pharmaceutical composition comprising an extended release non-steroidal anti-inflammatory agent and an immediate release prostaglandin
ATE262893T1 (de) Darreichungsformen zur behandlung von oralen mykosen
ATE410152T1 (de) Therapeutisches system mit amoxicillin und clavulansäure
DE69803670T2 (de) Tiagabinhaltige arzneizubereitungen mit gesteuerter wirkstoffverabreichung
HUP0400495A2 (hu) Apomorfin szájnyálkahártyán keresztül történő adagolására szolgáló orális készítmény
JP2009507850A5 (de)
JP2003523385A5 (de)

Legal Events

Date Code Title Description
8364 No opposition during term of opposition